Cargando…
Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)—a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma
BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) remain a substantial burden to global health. Cell-free circulating tumour DNA (ctDNA) is an emerging biomarker but has not been studied sufficiently in HNSCC. METHODS: We conducted a single-centre prospective cohort study to investigate ctDN...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023460/ https://www.ncbi.nlm.nih.gov/pubmed/35132238 http://dx.doi.org/10.1038/s41416-022-01716-7 |
_version_ | 1784690355274252288 |
---|---|
author | Flach, Susanne Howarth, Karen Hackinger, Sophie Pipinikas, Christodoulos Ellis, Pete McLay, Kirsten Marsico, Giovanni Forshew, Tim Walz, Christoph Reichel, Christoph A. Gires, Olivier Canis, Martin Baumeister, Philipp |
author_facet | Flach, Susanne Howarth, Karen Hackinger, Sophie Pipinikas, Christodoulos Ellis, Pete McLay, Kirsten Marsico, Giovanni Forshew, Tim Walz, Christoph Reichel, Christoph A. Gires, Olivier Canis, Martin Baumeister, Philipp |
author_sort | Flach, Susanne |
collection | PubMed |
description | BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) remain a substantial burden to global health. Cell-free circulating tumour DNA (ctDNA) is an emerging biomarker but has not been studied sufficiently in HNSCC. METHODS: We conducted a single-centre prospective cohort study to investigate ctDNA in patients with p16-negative HNSCC who received curative-intent primary surgical treatment. Whole-exome sequencing was performed on formalin-fixed paraffin-embedded (FFPE) tumour tissue. We utilised RaDaR(TM), a highly sensitive personalised assay using deep sequencing for tumour-specific variants, to analyse serial pre- and post-operative plasma samples for evidence of minimal residual disease and recurrence. RESULTS: In 17 patients analysed, personalised panels were designed to detect 34 to 52 somatic variants. Data show ctDNA detection in baseline samples taken prior to surgery in 17 of 17 patients. In post-surgery samples, ctDNA could be detected at levels as low as 0.0006% variant allele frequency. In all cases with clinical recurrence to date, ctDNA was detected prior to progression, with lead times ranging from 108 to 253 days. CONCLUSIONS: This study illustrates the potential of ctDNA as a biomarker for detecting minimal residual disease and recurrence in HNSCC and demonstrates the feasibility of personalised ctDNA assays for the detection of disease prior to clinical recurrence. |
format | Online Article Text |
id | pubmed-9023460 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-90234602022-04-28 Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)—a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma Flach, Susanne Howarth, Karen Hackinger, Sophie Pipinikas, Christodoulos Ellis, Pete McLay, Kirsten Marsico, Giovanni Forshew, Tim Walz, Christoph Reichel, Christoph A. Gires, Olivier Canis, Martin Baumeister, Philipp Br J Cancer Article BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) remain a substantial burden to global health. Cell-free circulating tumour DNA (ctDNA) is an emerging biomarker but has not been studied sufficiently in HNSCC. METHODS: We conducted a single-centre prospective cohort study to investigate ctDNA in patients with p16-negative HNSCC who received curative-intent primary surgical treatment. Whole-exome sequencing was performed on formalin-fixed paraffin-embedded (FFPE) tumour tissue. We utilised RaDaR(TM), a highly sensitive personalised assay using deep sequencing for tumour-specific variants, to analyse serial pre- and post-operative plasma samples for evidence of minimal residual disease and recurrence. RESULTS: In 17 patients analysed, personalised panels were designed to detect 34 to 52 somatic variants. Data show ctDNA detection in baseline samples taken prior to surgery in 17 of 17 patients. In post-surgery samples, ctDNA could be detected at levels as low as 0.0006% variant allele frequency. In all cases with clinical recurrence to date, ctDNA was detected prior to progression, with lead times ranging from 108 to 253 days. CONCLUSIONS: This study illustrates the potential of ctDNA as a biomarker for detecting minimal residual disease and recurrence in HNSCC and demonstrates the feasibility of personalised ctDNA assays for the detection of disease prior to clinical recurrence. Nature Publishing Group UK 2022-02-07 2022-05-03 /pmc/articles/PMC9023460/ /pubmed/35132238 http://dx.doi.org/10.1038/s41416-022-01716-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Flach, Susanne Howarth, Karen Hackinger, Sophie Pipinikas, Christodoulos Ellis, Pete McLay, Kirsten Marsico, Giovanni Forshew, Tim Walz, Christoph Reichel, Christoph A. Gires, Olivier Canis, Martin Baumeister, Philipp Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)—a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma |
title | Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)—a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma |
title_full | Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)—a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma |
title_fullStr | Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)—a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma |
title_full_unstemmed | Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)—a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma |
title_short | Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)—a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma |
title_sort | liquid biopsy for minimal residual disease detection in head and neck squamous cell carcinoma (lioness)—a personalised circulating tumour dna analysis in head and neck squamous cell carcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023460/ https://www.ncbi.nlm.nih.gov/pubmed/35132238 http://dx.doi.org/10.1038/s41416-022-01716-7 |
work_keys_str_mv | AT flachsusanne liquidbiopsyforminimalresidualdiseasedetectioninheadandnecksquamouscellcarcinomalionessapersonalisedcirculatingtumourdnaanalysisinheadandnecksquamouscellcarcinoma AT howarthkaren liquidbiopsyforminimalresidualdiseasedetectioninheadandnecksquamouscellcarcinomalionessapersonalisedcirculatingtumourdnaanalysisinheadandnecksquamouscellcarcinoma AT hackingersophie liquidbiopsyforminimalresidualdiseasedetectioninheadandnecksquamouscellcarcinomalionessapersonalisedcirculatingtumourdnaanalysisinheadandnecksquamouscellcarcinoma AT pipinikaschristodoulos liquidbiopsyforminimalresidualdiseasedetectioninheadandnecksquamouscellcarcinomalionessapersonalisedcirculatingtumourdnaanalysisinheadandnecksquamouscellcarcinoma AT ellispete liquidbiopsyforminimalresidualdiseasedetectioninheadandnecksquamouscellcarcinomalionessapersonalisedcirculatingtumourdnaanalysisinheadandnecksquamouscellcarcinoma AT mclaykirsten liquidbiopsyforminimalresidualdiseasedetectioninheadandnecksquamouscellcarcinomalionessapersonalisedcirculatingtumourdnaanalysisinheadandnecksquamouscellcarcinoma AT marsicogiovanni liquidbiopsyforminimalresidualdiseasedetectioninheadandnecksquamouscellcarcinomalionessapersonalisedcirculatingtumourdnaanalysisinheadandnecksquamouscellcarcinoma AT forshewtim liquidbiopsyforminimalresidualdiseasedetectioninheadandnecksquamouscellcarcinomalionessapersonalisedcirculatingtumourdnaanalysisinheadandnecksquamouscellcarcinoma AT walzchristoph liquidbiopsyforminimalresidualdiseasedetectioninheadandnecksquamouscellcarcinomalionessapersonalisedcirculatingtumourdnaanalysisinheadandnecksquamouscellcarcinoma AT reichelchristopha liquidbiopsyforminimalresidualdiseasedetectioninheadandnecksquamouscellcarcinomalionessapersonalisedcirculatingtumourdnaanalysisinheadandnecksquamouscellcarcinoma AT giresolivier liquidbiopsyforminimalresidualdiseasedetectioninheadandnecksquamouscellcarcinomalionessapersonalisedcirculatingtumourdnaanalysisinheadandnecksquamouscellcarcinoma AT canismartin liquidbiopsyforminimalresidualdiseasedetectioninheadandnecksquamouscellcarcinomalionessapersonalisedcirculatingtumourdnaanalysisinheadandnecksquamouscellcarcinoma AT baumeisterphilipp liquidbiopsyforminimalresidualdiseasedetectioninheadandnecksquamouscellcarcinomalionessapersonalisedcirculatingtumourdnaanalysisinheadandnecksquamouscellcarcinoma |